Sign in
CompletedNo phase

Effectiveness and Safety of Corneal Collagen Cross Linking After Induction of Stromal Emphysema in Keratoconus

Key facts

Who runs it
Cairo University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
39 people enrolled
Started
1 Oct 2022
Ended
1 Oct 2024
Type of study
Interventional
Treatments tested
  • Corneal collagen cross-linking with induction of corneal stromal emphysema
Record updated
23 February 2026

Who can take part

Age
17 years to 33 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Progressive KC proven by clinical examination, tomography, and pachymetry
  • Thinnest corneal location thickness between 390 to 450 microns

Who cannot take part

  • Previous ocular Trauma or Surgery
  • Collagen vascular disease, autoimmune disease and patients receiving immunosuppressive therapy
  • History of herpetic eye disease
  • Ocular surface disease and dry eye disease
  • Nystagmus or other conditions that interfere with patient's fixation
  • Diabetes mellitus
  • Central corneal scarring
  • Cornea guttata
  • Vernal and atopic keratoconjunctivitis
  • Cataract
  • Glaucoma, intraocular pressure less than 10 or more than 21 mmHg
  • Posterior segment abnormalities
  • pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

in this study we evaluated the effectiveness and safety of corneal collagen cross-linking in keratoconic eyes with thin cornea after induction of stromal emphysema prior to riboflavin instillation and UV-A corneal irradiation

The group in the trial

  • Patients with progressive keratoconusOther group

    Treatment: Corneal collagen cross-linking with induction of corneal stromal emphysema

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 February 2026